{"url_path":"/sec/spro/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-221567-index.html","accession_number":"0001193125-26-221567","cik":"0001701108","ticker":"SPRO","issuer_name":"Spero Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-221567-index.html","primary_entity_key":"0001701108","primary_entity_name":"Spero Therapeutics, Inc."},"word_count":94,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits\n\n \n\n(d)\n\nExhibits\n\n \n\nExhibit\nNo.\n\n  \n\nDescription\n\n99.1\n  \n[Press release issued by Spero Therapeutics, Inc. on May 13, 2026](d147628dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101)\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate: May 13, 2026\n \n\n \nSPERO THERAPEUTICS, INC.\n\n \n\n \nBy:\n \n\n/s/ Esther Rajavelu\n\n \n\n \n\n \nEsther Rajavelu\n\n \n\n \n\n \nChief Executive Officer, Chief Financial Officer and Chief Business Officer"}